ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
aTYR PHARMA INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.17−0.00 (-1.32%)
Close on Oct 19, 2026
- Market cap
- $16.84M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
41.4%
41M of 98M shares
Institutional holders
90
16 new, 35 sold out
Net institutional buying
-15M
In Q2 2026
Insider trades, 12 months
1 buys · 3 sales
Net bought $43.71K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Voting Shares Irrevocable Trust | 8,509,678 | 8.68% | 13G (passive) amendment | Jun 30, 2026 |
| J. Christopher Donahue | 4,965,414 | 5.06% | 13G (passive) amendment | Sep 30, 2026 |
| Federated Hermes, Inc. | 14,666,600 | 17.47% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ATYR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 8,509,678 | 8.68% | $5.08M | −2,000,000 | 0.01% |
| Vanguard Capital Management LLC | 3,808,091 | 3.88% | $2.27M | −4,041 | 0.00% |
| Kalehua Capital Management LLC | 3,576,334 | 3.65% | $2.13M | New | 0.68% |
| Gsa Capital Partners Llp | 3,454,863 | 3.52% | $2.06K | +1,770,277 | 0.13% |
| Aqr Capital Management LLC | 2,610,548 | 2.66% | $1.56M | +2,114,530 | 0.00% |
| FMR LLC | 2,471,418 | 2.52% | $1.47M | −12,235,425 | 0.00% |
| BlackRock, Inc. | 1,827,332 | 1.86% | $1.09M | −4,616,572 | 0.00% |
| Jane Street Group, LLC | 1,721,297 | 1.75% | $1.03M | +1,672,795 | 0.00% |
| UBS Group AG | 1,531,151 | 1.56% | $914.10K | −2,336,062 | 0.00% |
| Morgan Stanley | 1,343,636 | 1.37% | $801.88K | +118,169 | 0.00% |
| Two Sigma Investments, LP | 1,245,147 | 1.27% | $743.10K | +100,582 | 0.00% |
| Citadel Advisors LLC | 1,242,067 | 1.27% | $741.27K | +1,194,695 | 0.00% |
| Geode Capital Management, LLC | 1,177,020 | 1.20% | $702.73K | −1,208,465 | 0.00% |
| Susquehanna International Group, Llp | 747,039 | 0.76% | $445.83K | −119,705 | 0.00% |
| Millennium Management LLC | 656,051 | 0.67% | $391.53K | −985,195 | 0.00% |
| Goldman Sachs Group Inc | 641,208 | 0.65% | $382.67K | +357,972 | 0.00% |
| Vanguard Fiduciary Trust Co | 576,125 | 0.59% | $343.95K | −75,707 | 0.00% |
| State Street Corp | 494,951 | 0.50% | $295.39K | −1,259,448 | 0.00% |
| Marshall Wace, Llp | 368,120 | 0.38% | $220.87K | +230,002 | 0.00% |
| XTX Topco Ltd | 226,678 | 0.23% | $135.28K | +115,255 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 90 | 41M | 41.4% | 16 / 29 | 30 / 35 | 12M | 28M |
| Q1 2026 | 111 | 56M | 57.1% | 36 / 26 | 32 / 8 | 11M | 5M |
| Q4 2025 | 84 | 55M | 55.9% | 16 / 24 | 25 / 34 | 6M | 13M |
| Q3 2025 | 103 | 62M | 63.3% | 34 / 33 | 25 / 39 | 15M | 20M |
| Q2 2025 | 110 | 66M | 67.8% | 52 / 25 | 24 / 29 | 12M | 8M |
| Q1 2025 | 87 | 62M | 63.0% | 26 / 36 | 14 / 16 | 13M | 6M |
| Q4 2024 | 77 | 55M | 56.0% | 30 / 24 | 12 / 8 | 13M | 5M |
| Q3 2024 | 56 | 48M | 48.8% | 15 / 15 | 12 / 5 | 4M | 6M |
| Q2 2024 | 47 | 51M | 52.1% | 8 / 22 | 11 / 17 | 12M | 3M |
| Q1 2024 | 56 | 42M | 42.7% | 15 / 21 | 10 / 5 | 5M | 5M |
| Q4 2023 | 46 | 41M | 42.1% | 9 / 15 | 10 / 3 | 9M | 4M |
| Q3 2023 | 40 | 37M | 37.4% | 7 / 6 | 18 / 8 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ATYR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 4,367,290 | 4.45% | $2.12M | 0.04% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 4,216,832 | 4.30% | $2.29M | 0.00% | May 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 4,061,288 | 4.14% | $1.97M | 0.07% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,650,788 | 2.70% | $1.58M | 0.00% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,754,594 | 1.79% | $951.87K | 0.02% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 1,054,556 | 1.08% | $629.36K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 550,058 | 0.56% | $298.41K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 488,823 | 0.50% | $265.19K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 168,117 | 0.17% | $91.20K | 0.00% | May 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 146,027 | 0.15% | $87.15K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 145,359 | 0.15% | $78.86K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 85,881 | 0.09% | $46.59K | 0.00% | May 31, 2026 |
| Federated Hermes Kaufmann Fund II | 81,100 | 0.08% | $48.40K | 0.04% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 66,669 | 0.07% | $36.17K | 0.00% | May 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 66,034 | 0.07% | $39.41K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sanjay Shukla | President and CEO, Director | 153,553 | 0.16% | Feb 4, 2026 |
| Jill Marie Broadfoot | Chief Financial Officer | 37,296 | 0.04% | Feb 4, 2026 |
| Nancy Denyes | General Counsel | 33,124 | 0.03% | Feb 4, 2026 |
| Paul Schimmel | Director | 2,201,056 | 2.24% | May 28, 2026 |
| Svetlana Lucas | Director | 6,000 | 0.01% | May 13, 2026 |
| Sara Zaknoen | Director | 6,000 | 0.01% | May 13, 2026 |
| Eric Benevich | Director | – | – | May 13, 2026 |
| Timothy Coughlin | Director | 56,000 | 0.06% | May 13, 2026 |
| Jane A. Gross | Director | 9,750 | 0.01% | May 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Paul Schimmel Director | May 27, 2026 | Buy | +100,000 | $0.50 | $50.00K | 779,143 |
| Nancy Denyes General Counsel | Feb 4, 2026 | Sale | −1,118 | $0.98 | $1.10K | 33,124 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 4, 2026 | Sale | −1,558 | $0.98 | $1.53K | 37,296 |
| Sanjay Shukla President and CEO, Director | Feb 4, 2026 | Sale | −3,745 | $0.98 | $3.67K | 153,553 |
| Nancy Denyes General Counsel | Feb 3, 2026 | Option exercise | +2,687 | – | – | 34,242 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 3, 2026 | Option exercise | +3,750 | – | – | 38,854 |
| Sanjay Shukla President and CEO, Director | Feb 3, 2026 | Option exercise | +10,375 | – | – | 157,298 |
| Paul Schimmel Director | Oct 9, 2025 | Buy | +317,999 | $0.94 | $298.92K | 1,413,023 |
| Paul Schimmel Director | Oct 8, 2025 | Buy | +682,001 | $0.90 | $613.80K | 1,095,024 |
| Jane A. Gross Director | Mar 17, 2025 | Buy | +3,750 | $4.00 | $15.00K | 9,750 |
| Nancy Denyes General Counsel | Feb 4, 2025 | Sale | −899 | $3.78 | $3.40K | 26,555 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 4, 2025 | Sale | −1,254 | $3.78 | $4.74K | 31,763 |
| Nancy Denyes General Counsel | Feb 3, 2025 | Option exercise | +2,687 | – | – | 27,454 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 3, 2025 | Option exercise | +3,750 | – | – | 33,017 |
| Sanjay Shukla President and CEO, Director | Feb 3, 2025 | Option exercise | +10,375 | – | – | 146,923 |
| Paul Schimmel Director | Jul 24, 2024 | Buy | +52,300 | $1.93 | $100.94K | 413,023 |
| Paul Schimmel Director | Jul 23, 2024 | Buy | +6,648 | $1.82 | $12.10K | 360,723 |
| Paul Schimmel Director | Jul 22, 2024 | Buy | +41,052 | $1.74 | $71.43K | 354,075 |
| Nancy Denyes General Counsel | Jun 5, 2024 | Buy | +5,000 | $1.86 | $9.30K | 22,267 |
| Sanjay Shukla President and CEO, Director | May 31, 2024 | Buy | +20,000 | $1.81 | $36.20K | 136,548 |
| Jill Marie Broadfoot Chief Financial Officer | May 31, 2024 | Buy | +5,000 | $1.79 | $8.95K | 27,960 |
| Timothy Coughlin Director | May 30, 2024 | Buy | +50,000 | $1.75 | $87.50K | 56,000 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 6, 2024 | Sale | −1,590 | $1.69 | $2.69K | 20,821 |
| Nancy Denyes General Counsel | Feb 5, 2024 | Option exercise | +2,688 | – | – | 14,767 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 5, 2024 | Option exercise | +3,750 | – | – | 22,411 |
| Sanjay Shukla President and CEO, Director | Feb 5, 2024 | Option exercise | +10,375 | – | – | 116,548 |
| Sanjay Shukla President and CEO, Director | Dec 12, 2023 | Buy | +12,000 | $1.18 | $14.16K | 106,173 |
| Sanjay Shukla President and CEO, Director | Dec 11, 2023 | Buy | +3,000 | $1.17 | $3.51K | 94,173 |
| Sanjay Shukla President and CEO, Director | Nov 13, 2023 | Buy | +13,578 | $1.11 | $15.07K | 91,173 |
| Sanjay Shukla President and CEO, Director | Nov 10, 2023 | Buy | +1,422 | $1.14 | $1.62K | 77,595 |
| Sanjay Shukla President and CEO, Director | Jul 28, 2023 | Buy | +15,000 | $2.01 | $30.15K | 76,173 |
| Timothy Coughlin Director | May 17, 2023 | Gift | −6,000 | – | – | 0 |
| Timothy Coughlin Director | May 17, 2023 | Gift | +6,000 | – | – | 6,000 |
| Paul Schimmel Director | May 10, 2023 | Buy | +200,000 | $2.25 | $450.00K | 313,023 |
| Svetlana Lucas Director | Apr 26, 2023 | Option exercise | +6,000 | – | – | 6,000 |
| John K. Clarke Director | Apr 26, 2023 | Option exercise | +6,000 | – | – | 19,797 |
| Jane A. Gross Director | Apr 26, 2023 | Option exercise | +6,000 | – | – | 6,000 |
| Paul Schimmel Director | Apr 26, 2023 | Option exercise | +6,000 | – | – | 8,890 |
| Sara Zaknoen Director | Apr 26, 2023 | Option exercise | +6,000 | – | – | 6,000 |
| Timothy Coughlin Director | Apr 26, 2023 | Option exercise | +6,000 | – | – | 6,000 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 6, 2023 | Sale | −1,566 | $2.36 | $3.70K | 15,460 |
| Sanjay Shukla President and CEO, Director | Feb 3, 2023 | Option exercise | +10,375 | – | – | 61,173 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 3, 2023 | Option exercise | +3,750 | – | – | 17,026 |
| Nancy Denyes General Counsel | Feb 3, 2023 | Option exercise | +2,688 | – | – | 7,079 |
| Sanjay Shukla President and CEO, Director | Nov 21, 2022 | Buy | +10,000 | $2.14 | $21.40K | 50,798 |
| Sanjay Shukla President and CEO, Director | Jul 1, 2022 | Buy | +15,000 | $2.88 | $43.20K | 40,798 |
| Jill Marie Broadfoot Chief Financial Officer | Jan 13, 2022 | Buy | +1,923 | $6.75 | $12.98K | 12,112 |
| Sanjay Shukla President and CEO, Director | Jan 7, 2022 | Buy | +5,000 | $6.76 | $33.80K | 25,798 |
| Sanjay Shukla President and CEO, Director | Nov 15, 2021 | Buy | +2,500 | $8.58 | $21.45K | 20,798 |
| Paul Schimmel Director | Sep 20, 2021 | Gift | +250,000 | – | – | 679,143 |
| Paul Schimmel Director | Sep 20, 2021 | Buy | +250,000 | $8.00 | $2.00M | 252,890 |
| Paul Schimmel Director | Sep 20, 2021 | Gift | −250,000 | – | – | 2,890 |
| John K. Clarke Director | May 21, 2021 | Sale | −2,500 | $4.34 | $10.85K | 108,083 |
| Sanjay Shukla President and CEO, Director | May 18, 2021 | Buy | +10,000 | $4.01 | $40.10K | 18,298 |
| Paul Schimmel Director | May 18, 2021 | Buy | +50,000 | $3.98 | $199.00K | 113,023 |
| Sanjay Shukla President and CEO, Director | Feb 9, 2021 | Sale | −778 | $7.66 | $5.96K | 8,298 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 9, 2021 | Sale | −390 | $7.66 | $2.99K | 9,833 |
| Sanjay Shukla President and CEO, Director | Feb 6, 2021 | Option exercise | +1,785 | – | – | 9,076 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 6, 2021 | Option exercise | +892 | – | – | 10,223 |
| John K. Clarke Director | Sep 2, 2020 | Sale | −7,260 | $4.01 | $29.11K | 110,583 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.